<< Read Full Article
<< Read Full Article
ZymoGenetics(ZGEN Quote) has landed Bristol-Myers Squibb(BMY Quote) as its worldwide development partner for PEG-Interferon lambda, a new experimental treatment for hepatitis C.
Bristol-Myers has agreed to pay $85 million upfront to ZymoGenetics for rights to PEG-Interferon lambda, which is currently in phase I studies. Bristol-Myers will pay another $20 million license fee to ZymoGenetics in 2009, the companies announced Monday.
Long-acting interferons taken by weekly injection, sold by Schering-Plough(SGP Quote) and Roche, are a current mainstay of hepatitis C treatment, but the drugs produce flu-like symptoms among other side effects and are generally not tolerated well by patients. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet